1 5949 101 TARGETING THE PRC2-DEPENDENT EPIGENETIC PROGRAM ALLEVIATES URINARY TRACT INFECTIONS. URINARY TRACT INFECTION (UTI) IS A PERVASIVE HEALTH PROBLEM WORLDWIDE. PATIENTS WITH A HISTORY OF UTIS SUFFER INCREASED RISK OF RECURRENT INFECTIONS, A MAJOR RISK OF ANTIBIOTIC RESISTANCE. HERE, WE SHOW THAT BLADDER INFECTIONS INDUCE EXPRESSION OF EZH2 IN BLADDER UROTHELIAL CELLS. EZH2 IS THE METHYLTRANSFERASE OF POLYCOMB REPRESSOR COMPLEX 2 (PRC2)-A POTENT EPIGENETIC REGULATOR. UROTHELIUM-SPECIFIC INACTIVATION OF PRC2 RESULTS IN REDUCED URINE BACTERIAL BURDEN, MUTED INFLAMMATORY RESPONSE, AND DECREASED ACTIVITY OF THE NF-KAPPAB SIGNALING PATHWAY. PRC2 INACTIVATION ALSO FACILITATES PROPER REGENERATION AFTER UROTHELIAL DAMAGE FROM UTIS, BY ATTENUATING BASAL CELL HYPERPLASIA AND INCREASING UROTHELIAL DIFFERENTIATION. IN ADDITION, TREATMENT WITH EZH2-SPECIFIC SMALL-MOLECULE INHIBITORS IMPROVES OUTCOMES OF THE CHRONIC AND SEVERE BLADDER INFECTIONS IN MICE. THESE FINDINGS COLLECTIVELY SUGGEST THAT THE PRC2-DEPENDENT EPIGENETIC REPROGRAMING CONTROLS THE AMPLITUDE OF INFLAMMATION AND SEVERITY OF UTIS AND THAT EZH2 INHIBITORS MAY BE A VIABLE NON-ANTIBIOTIC STRATEGY TO MANAGE CHRONIC AND SEVERE UTIS. 2023 2 6671 33 UROPATHOGENIC ESCHERICHIA COLI INFECTION-INDUCED EPITHELIAL TRAINED IMMUNITY IMPACTS URINARY TRACT DISEASE OUTCOME. PREVIOUS URINARY TRACT INFECTIONS (UTIS) CAN PREDISPOSE ONE TO FUTURE INFECTIONS; HOWEVER, THE UNDERLYING MECHANISMS AFFECTING RECURRENCE ARE POORLY UNDERSTOOD. WE PREVIOUSLY FOUND THAT UTIS IN MICE CAUSE DIFFERENTIAL BLADDER EPITHELIAL (UROTHELIAL) REMODELLING, DEPENDING ON DISEASE OUTCOME, THAT IMPACTS SUSCEPTIBILITY TO RECURRENT UTI. HERE WE COMPARED UROTHELIAL STEM CELL (USC) LINES ISOLATED FROM MICE WITH A HISTORY OF EITHER RESOLVED OR CHRONIC UROPATHOGENIC ESCHERICHIA COLI (UPEC) INFECTION, ELUCIDATING EVIDENCE OF MOLECULAR IMPRINTING THAT INVOLVED EPIGENETIC CHANGES, INCLUDING DIFFERENCES IN CHROMATIN ACCESSIBILITY, DNA METHYLATION AND HISTONE MODIFICATION. EPIGENETIC MARKS IN USCS FROM CHRONICALLY INFECTED MICE ENHANCED CASPASE-1-MEDIATED CELL DEATH UPON UPEC INFECTION, PROMOTING BACTERIAL CLEARANCE. INCREASED PTGS2OS2 EXPRESSION ALSO OCCURRED, POTENTIALLY CONTRIBUTING TO SUSTAINED CYCLOOXYGENASE-2 EXPRESSION, BLADDER INFLAMMATION AND MUCOSAL WOUNDING-RESPONSES ASSOCIATED WITH SEVERE RECURRENT CYSTITIS. THUS, UPEC INFECTION ACTS AS AN EPI-MUTAGEN REPROGRAMMING THE UROTHELIAL EPIGENOME, LEADING TO UROTHELIAL-INTRINSIC REMODELLING AND TRAINING OF THE INNATE RESPONSE TO SUBSEQUENT INFECTION. 2023 3 1458 28 DISORDER OF G2-M CHECKPOINT CONTROL IN ANILINE-INDUCED CELL PROLIFERATION IN RAT SPLEEN. ANILINE, A TOXIC AROMATIC AMINE, IS KNOWN TO CAUSE HEMOPOIETIC TOXICITY BOTH IN HUMANS AND ANIMALS. ANILINE EXPOSURE ALSO LEADS TO TOXIC RESPONSE IN SPLEEN WHICH IS CHARACTERIZED BY SPLENOMEGALY, HYPERPLASIA, FIBROSIS AND THE EVENTUAL FORMATION OF TUMORS ON CHRONIC IN VIVO EXPOSURE. PREVIOUSLY, WE HAVE SHOWN THAT ANILINE EXPOSURE LEADS TO IRON OVERLOAD, OXIDATIVE DNA DAMAGE, AND INCREASED CELL PROLIFERATION, WHICH COULD EVENTUALLY CONTRIBUTE TO A TUMORIGENIC RESPONSE IN THE SPLEEN. DESPITE OUR DEMONSTRATION THAT CELL PROLIFERATION WAS ASSOCIATED WITH DEREGULATION OF G1 PHASE CYCLINS AND INCREASED EXPRESSION OF G1 PHASE CYCLIN-DEPENDENT KINASES (CDKS), MOLECULAR MECHANISMS, ESPECIALLY THE REGULATION OF G2 PHASE AND CONTRIBUTION OF EPIGENETIC MECHANISMS IN ANILINE-INDUCED SPLENIC CELLULAR PROLIFERATION REMAIN LARGELY UNCLEAR. THIS STUDY THEREFORE, MAINLY FOCUSED ON THE REGULATION OF G2 PHASE IN AN ANIMAL MODEL PRECEDING A TUMORIGENIC RESPONSE. MALE SPRAGUE-DAWLEY RATS WERE GIVEN ANILINE (0.5 MMOL/KG/DAY) IN DRINKING WATER OR DRINKING WATER ONLY (CONTROLS) FOR 30 DAYS, AND EXPRESSION OF G2 PHASE CYCLINS, CDK1, CDK INHIBITORS AND MIRNAS WERE MEASURED IN THE SPLEEN. ANILINE TREATMENT RESULTED IN SIGNIFICANT INCREASES IN CELL CYCLE REGULATORY PROTEINS, INCLUDING CYCLINS A, B AND CDK1, PARTICULARLY PHOSPHOR-CDK1, AND DECREASES IN CDK INHIBITORS P21 AND P27, WHICH COULD PROMOTE THE SPLENOCYTES TO GO THROUGH G2/M TRANSITION. OUR DATA ALSO SHOWED UPREGULATION OF TUMOR MARKERS TRX-1 AND REF-1 IN RATS TREATED WITH ANILINE. MORE IMPORTANTLY, WE OBSERVED LOWER EXPRESSION OF MIRNAS INCLUDING LET-7A, MIR-15B, MIR24, MIR-100 AND MIR-125, AND GREATER EXPRESSION OF CDK INHIBITOR REGULATORY MIRNAS SUCH AS MIR-181A, MIR-221 AND MIR-222 IN THE SPLEENS OF ANILINE-TREATED ANIMALS. OUR FINDINGS SUGGEST THAT SIGNIFICANT INCREASES IN THE EXPRESSION OF CYCLINS, CDK1 AND ABERRANT REGULATION OF MIRNAS COULD LEAD TO AN ACCELERATED G2/M TRANSITION OF THE SPLENOCYTES, AND POTENTIALLY TO A TUMORIGENIC RESPONSE ON CHRONIC ANILINE EXPOSURE. 2015 4 5601 28 RORALPHA IS CRUCIAL FOR ATTENUATED INFLAMMATORY RESPONSE TO MAINTAIN INTESTINAL HOMEOSTASIS. RETINOIC ACID-RELATED ORPHAN RECEPTOR ALPHA (RORALPHA) FUNCTIONS AS A TRANSCRIPTION FACTOR FOR VARIOUS BIOLOGICAL PROCESSES, INCLUDING CIRCADIAN RHYTHM, CANCER, AND METABOLISM. HERE, WE GENERATE INTESTINAL EPITHELIAL CELL (IEC)-SPECIFIC RORALPHA-DEFICIENT (RORALPHA(DELTAIEC)) MICE AND FIND THAT RORALPHA IS CRUCIAL FOR MAINTAINING INTESTINAL HOMEOSTASIS BY ATTENUATING NUCLEAR FACTOR KAPPAB (NF-KAPPAB) TRANSCRIPTIONAL ACTIVITY. RORALPHA(DELTAIEC) MICE EXHIBIT EXCESSIVE INTESTINAL INFLAMMATION AND HIGHLY ACTIVATED INFLAMMATORY RESPONSES IN THE DEXTRAN SULFATE SODIUM (DSS) MOUSE COLITIS MODEL. TRANSCRIPTOME ANALYSIS REVEALS THAT DELETION OF RORALPHA LEADS TO UP-REGULATION OF NF-KAPPAB TARGET GENES IN IECS. CHROMATIN IMMUNOPRECIPITATION ANALYSIS REVEALS CORECRUITMENT OF RORALPHA AND HISTONE DEACETYLASE 3 (HDAC3) ON NF-KAPPAB TARGET PROMOTERS AND SUBSEQUENT DISMISSAL OF CREB BINDING PROTEIN (CBP) AND BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) FOR TRANSCRIPTIONAL REPRESSION. TOGETHER, WE DEMONSTRATE THAT RORALPHA/HDAC3-MEDIATED ATTENUATION OF NF-KAPPAB SIGNALING CONTROLS THE BALANCE OF INFLAMMATORY RESPONSES, AND THERAPEUTIC STRATEGIES TARGETING THIS EPIGENETIC REGULATION COULD BE BENEFICIAL TO THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD). 2019 5 5049 23 PHARMACOLOGICAL INHIBITION OF RORC2 ENHANCES HUMAN TH17-TREG STABILITY AND FUNCTION. INFLAMMATORY BOWEL DISEASES (IBD) ARE CHRONIC CONDITIONS THAT RESULT FROM UNCONTROLLED INTESTINAL INFLAMMATION. PATHOGENIC TH17 CELLS, CHARACTERIZED BY PRODUCTION OF IL-17A IN THE ABSENCE OF IL-10, ARE THOUGHT TO CONTRIBUTE TO THIS INFLAMMATION, BUT IN HUMANS, ANTIBODY-MEDIATED BLOCKADE OF IL-17A IS AN INEFFECTIVE IBD THERAPY WHEREAS IL-23 BLOCKADE IS EFFECTIVE. HERE, WE INVESTIGATED THE EFFECTS OF PHARMACOLOGICAL INHIBITION OF RORC2, THE TH17 CELL LINEAGE-DEFINING TRANSCRIPTION FACTOR, ON IN VIVO-DIFFERENTIATED HUMAN TH17 CELLS AND TH17-LIKE TREGS (TH17-TREGS). BMS-336, A SMALL MOLECULE RORC2 INVERSE AGONIST, INHIBITED EXPRESSION OF RORC2-REGULATED GENES IN PERIPHERAL TH17 CELLS (CD4(+) CD25(-) CD127(+) CXCR3(-) CCR4(+) CCR6(+) ) IN A DOSE-DEPENDENT MANNER, WITH SIMILAR INHIBITORY EFFECTS ON LAMINAR PROPRIA MONONUCLEAR CELLS FROM IBD AND NON-IBD SUBJECTS. EXPOSURE OF PERIPHERAL TH17-TREGS (CD4(+) CD25(HI) CD127(LO) CXCR3(-) CCR4(+) CCR6(+) ) TO BMS-336 ALSO INHIBITED IL-17A PRODUCTION AND PREVENTED INFLAMMATORY CYTOKINE-INDUCED DESTABILIZATION, AS EVIDENCED BY PRESERVED FOXP3 EXPRESSION AND EPIGENETIC STATUS OF THE TREG-SPECIFIC DEMETHYLATION REGION. IN PARALLEL, RORC2 INHIBITION INCREASED THE PRODUCTION OF IL-10 IN TH17-TREGS, RESULTING IN ENHANCED SUPPRESSION OF INFLAMMATORY CYTOKINES FROM MYELOID CELLS. THUS, VIA ITS ABILITY TO SIMULTANEOUSLY INHIBIT TH17 CELLS AND ENHANCE THE STABILITY AND FUNCTION OF TH17-TREGS, PHARMACOLOGICAL INHIBITION OF RORC2 IS A PROMISING APPROACH TO SUPPRESS INFLAMMATION AND PROMOTE IMMUNE REGULATION IN IBD. 2020 6 5864 25 SUPPRESSION OF ELF4 IN ULCERATIVE COLITIS PREDISPOSES HOST TO COLORECTAL CANCER. ULCERATIVE COLITIS (UC) IS A CHRONIC INFLAMMATORY BOWEL DISEASE, CHARACTERIZED BY RELAPSING AND REMITTING COLON MUCOSAL INFLAMMATION. FOR PATIENTS SUFFERING FROM UC, A HIGHER RISK OF COLON CANCER HAS BEEN WIDELY RECOGNIZED. HERE, WE FOUND THAT ELF4 (-/-) MICE DEVELOPED COLON TUMORS WITH 3 CYCLES OF DEXTRAN SULFATE SODIUM SALT (DSS) TREATMENT ALONE. WE FURTHER SHOWED THAT ELF4 SUPPRESSION WAS PREVALENT IN BOTH PATIENTS WITH UC AND DSS-INDUCED MICE MODELS, AND THIS SUPPRESSION WAS CAUSED BY PROMOTER REGION METHYLATION. ELF4, UPON PARYLATION BY PARP1, TRANSCRIPTIONALLY REGULATED MULTIPLE DNA DAMAGE REPAIR MACHINERY COMPONENTS. CONSISTENTLY, ELF4 DEFICIENCY LEADS TO MORE SEVERE DNA DAMAGE BOTH IN VITRO AND IN VIVO. ORAL ADMINISTRATION OF MONTMORILLONITE POWDER CAN PREVENT THE REDUCTION OF ELF4 IN DSS-INDUCED COLITIS MODELS AND LOWER THE RISK OF COLON TUMOR DEVELOPMENT DURING AZOXYMETHANE (AOM) AND DSS INDUCED COLITIS-ASSOCIATED CANCER (CAC). THESE DATA PROVIDED ADDITIONAL MECHANISM OF CAC INITIATION AND SUPPORTED THE "EPIGENETIC PRIMING MODEL OF TUMOR INITIATION". 2021 7 4696 24 NF-KAPPAB REPRESSES RETINOIC ACID RECEPTOR-MEDIATED GPRC5A TRANSACTIVATION IN LUNG EPITHELIAL CELLS TO PROMOTE NEOPLASIA. CHRONIC INFLAMMATION IS ASSOCIATED WITH LUNG TUMORIGENESIS, IN WHICH NF-KAPPAB-MEDIATED EPIGENETIC REGULATION PLAYS A CRITICAL ROLE. LUNG TUMOR SUPPRESSOR G PROTEIN-COUPLED RECEPTOR, FAMILY C, MEMBER 5A (GPRC5A), IS REPRESSED IN MOST NON-SMALL CELL LUNG CANCER (NSCLC); HOWEVER, THE MECHANISMS REMAIN UNCLEAR. HERE, WE SHOW THAT NF-KAPPAB ACTS AS A TRANSCRIPTIONAL REPRESSOR IN SUPPRESSION OF GPRC5A. NF-KAPPAB INDUCED GPRC5A REPRESSION BOTH IN VITRO AND IN VIVO. INTRIGUINGLY, TRANSACTIVATION OF NF-KAPPAB DOWNSTREAM TARGETS WAS NOT REQUIRED, BUT THE TRANSACTIVATION DOMAIN OF RELA/P65 WAS REQUIRED FOR GPRC5A REPRESSION. NF-KAPPAB DID NOT BIND TO ANY POTENTIAL CIS-ELEMENT IN THE GPRC5A PROMOTER. INSTEAD, P65 WAS COMPLEXED WITH RETINOIC ACID RECEPTOR ALPHA/BETA (RARALPHA/BETA) AND RECRUITED TO THE RA RESPONSE ELEMENT SITE AT THE GPRC5A PROMOTER, RESULTING IN DISRUPTED RNA POLYMERASE II COMPLEXING AND SUPPRESSED TRANSCRIPTION. NOTABLY, PHOSPHORYLATION ON SERINE 276 OF P65 WAS REQUIRED FOR INTERACTION WITH RARALPHA/BETA AND REPRESSION OF GPRC5A. MOREOVER, NF-KAPPAB-MEDIATED EPIGENETIC REPRESSION WAS THROUGH SUPPRESSION OF ACETYLATED HISTONE H3K9 (H3K9AC), BUT NOT DNA METHYLATION OF THE CPG ISLANDS, AT THE GPRC5A PROMOTER. CONSISTENTLY, A HISTONE DEACETYLASE INHIBITOR, BUT NOT DNA METHYLATION INHIBITOR, RESTORED GPRC5A EXPRESSION IN NSCLC CELLS. THUS, NF-KAPPAB INDUCES TRANSCRIPTIONAL REPRESSION OF GPRC5A VIA A COMPLEX WITH RARALPHA/BETA AND MEDIATES EPIGENETIC REPRESSION VIA SUPPRESSION OF H3K9AC. 2023 8 5064 22 PHOSPHORYLATION OF RELA/P65 PROMOTES DNMT-1 RECRUITMENT TO CHROMATIN AND REPRESSES TRANSCRIPTION OF THE TUMOR METASTASIS SUPPRESSOR GENE BRMS1. THE MAJORITY OF PATIENTS WITH LUNG CANCER PRESENT WITH METASTATIC DISEASE. CHRONIC INFLAMMATION AND SUBSEQUENT ACTIVATION OF NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) HAVE BEEN ASSOCIATED WITH THE DEVELOPMENT OF CANCERS. THE RELA/P65 SUBUNIT OF NF-KAPPAB IS TYPICALLY ASSOCIATED WITH TRANSCRIPTIONAL ACTIVATION. IN THIS REPORT WE SHOW THAT RELA/P65 CAN FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR THROUGH ENHANCED METHYLATION OF THE BRMS1 (BREAST CANCER METASTASIS SUPPRESSOR 1) METASTASIS SUPPRESSOR GENE PROMOTER VIA DIRECT RECRUITMENT OF DNMT-1 (DNA (CYTOSINE-5)-METHYLTRANSFERASE 1) TO CHROMATIN IN RESPONSE TO TUMOR NECROSIS FACTOR (TNF). TNF-MEDIATED PHOSPHORYLATION OF S276 ON RELA/P65 IS REQUIRED FOR RELA/P65-DNMT-1 INTERACTIONS, CHROMATIN LOADING OF DNMT-1 AND SUBSEQUENT BRMS1 PROMOTER METHYLATION AND TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR IS PROMOTER SPECIFIC, AS THE NF-KAPPAB-REGULATED GENE CIAP2 (CELLULAR INHIBITOR OF APOPTOSIS 2) IS TRANSCRIPTIONALLY ACTIVATED WHEREAS BRMS1 IS REPRESSED UNDER IDENTICAL CONDITIONS. SMALL-MOLECULE INHIBITION OF EITHER OF THE MINIMAL INTERACTING DOMAINS BETWEEN RELA/P65-DNMT-1 AND RELA/P65-BRMS1 PROMOTER ABROGATES BRMS1 METHYLATION AND ITS TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO DIRECTLY RECRUIT DNMT-1 TO CHROMATIN, RESULTING IN PROMOTER-SPECIFIC METHYLATION AND TRANSCRIPTIONAL REPRESSION OF TUMOR METASTASIS SUPPRESSOR GENE BRMS1, HIGHLIGHTS A NEW MECHANISM THROUGH WHICH NF-KAPPAB CAN REGULATE METASTATIC DISEASE, AND OFFERS A POTENTIAL TARGET FOR NEWER-GENERATION EPIGENETIC ONCOPHARMACEUTICALS. 2012 9 131 27 A2B ADENOSINE SIGNALING REPRESSES CIITA TRANSCRIPTION VIA AN EPIGENETIC MECHANISM IN VASCULAR SMOOTH MUSCLE CELLS. CHRONIC INFLAMMATION PLAYS A MAJOR ROLE IN THE PATHOGENESIS OF ATHEROSCLEROSIS. VASCULAR SMOOTH MUSCLE CELLS (VSMC), BY EXPRESSING AND PRESENTING MAJOR HISTOCOMPATIBILITY COMPLEX II (MHC II) MOLECULES, HELP RECRUIT T LYMPHOCYTE AND INITIATE THE INFLAMMATORY RESPONSE WITHIN THE VASCULATURE. WE HAVE PREVIOUSLY SHOWN THAT VSMCS ISOLATED FROM MICE WITH DEFICIENT ADENOSINE A2B RECEPTOR (A2B-NULL) EXHIBIT HIGHER EXPRESSION OF CLASS II TRANSACTIVATOR (CIITA), THE MASTER REGULATOR OF MHC II TRANSCRIPTION, COMPARED TO WILD TYPE LITTERMATES. HERE WE REPORT THAT ACTIVATION OF A2B ADENOSINE SIGNALING SUPPRESSES CIITA EXPRESSION IN HUMAN AORTIC SMOOTH MUSCLE CELLS. DOWN-REGULATION OF CIITA EXPRESSION WAS LARGELY ATTRIBUTABLE TO TRANSCRIPTIONAL REPRESSION OF TYPE III AND IV PROMOTERS. CHROMATIN IMMUNOPRECIPITATION (CHIP) ANALYSES REVEALED THAT A2B SIGNALING REPRESSED CIITA TRANSCRIPTION BY ATTENUATING SPECIFIC HISTONE MODIFICATIONS ON THE CIITA PROMOTERS IN A STAT1-DEPENDENT MANNER. STAT1 INTERACTED WITH PCAF/GCN5, HISTONE H3K9 ACETYLTRANSFERASES, AND WDR5, A KEY COMPONENT OF THE MAMMALIAN H3K4 METHYLTRANSFERASE COMPLEX, TO ACTIVATE CIITA TRANSCRIPTION. A2B SIGNALING PREVENTED RECRUITMENT OF PCAF/GCN5 AND WDR5 TO THE CIITA PROMOTERS IN A STAT1-DEPENDENT MANNER. IN CONCLUSION, OUR DATA SUGGEST THAT ADENOSINE A2B SIGNALING REPRESSES CIITA TRANSCRIPTION IN VSMCS BY MANIPULATING THE INTERACTION BETWEEN STAT1 AND THE EPIGENETIC MACHINERY. 2015 10 4048 30 MAINTENANCE AND PHARMACOLOGIC TARGETING OF ROR1 PROTEIN LEVELS VIA UHRF1 IN T(1;19) PRE-B-ALL. EXPRESSION OF THE TRANSMEMBRANE PSEUDOKINASE ROR1 IS REQUIRED FOR SURVIVAL OF T(1;19)-PRE-B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T(1;19) PRE-B-ALL), CHRONIC LYMPHOCYTIC LEUKEMIA, AND MANY SOLID TUMORS. HOWEVER, TARGETING ROR1 WITH SMALL-MOLECULES HAS BEEN CHALLENGING DUE TO THE ABSENCE OF ROR1 KINASE ACTIVITY. TO IDENTIFY GENES THAT REGULATE ROR1 EXPRESSION AND MAY, THEREFORE, SERVE AS SURROGATE DRUG TARGETS, WE EMPLOYED AN SIRNA SCREENING APPROACH AND DETERMINED THAT THE EPIGENETIC REGULATOR AND E3 UBIQUITIN LIGASE, UHRF1, IS REQUIRED FOR T(1;19) PRE-B-ALL CELL VIABILITY IN A ROR1-DEPENDENT MANNER. UPON UHRF1 SILENCING, ROR1 PROTEIN IS REDUCED WITHOUT ALTERING ROR1 MRNA, AND ECTOPICALLY EXPRESSED UHRF1 IS SUFFICIENT TO INCREASE ROR1 LEVELS. ADDITIONALLY, PROTEASOME INHIBITION RESCUES LOSS OF ROR1 PROTEIN AFTER UHRF1 SILENCING, SUGGESTING A ROLE FOR THE PROTEASOME IN THE UHRF1-ROR1 AXIS. FINALLY, WE SHOW THAT ROR1-POSITIVE CELLS ARE TWICE AS SENSITIVE TO THE UHRF1-TARGETING DRUG, NAPHTHAZARIN, AND UNDERGO INCREASED APOPTOSIS COMPARED TO ROR1-NEGATIVE CELLS. NAPHTHAZARIN ELICITS REDUCED EXPRESSION OF UHRF1 AND ROR1, AND COMBINATION OF NAPHTHAZARIN WITH INHIBITORS OF PRE-B CELL RECEPTOR SIGNALING RESULTS IN FURTHER REDUCTION OF CELL SURVIVAL COMPARED WITH EITHER INHIBITOR ALONE. THEREFORE, OUR WORK REVEALS A MECHANISM BY WHICH UHRF1 STABILIZES ROR1, SUGGESTING A POTENTIAL TARGETING STRATEGY TO INHIBIT ROR1 IN T(1;19) PRE-B-ALL AND OTHER MALIGNANCIES. 2018 11 3998 24 LOSS OF EPIGENETIC MODIFICATION DRIVEN BY THE FOXP3 TRANSCRIPTION FACTOR LEADS TO REGULATORY T CELL INSUFFICIENCY. REGULATORY T (TREG) CELLS, DRIVEN BY THE FOXP3 TRANSCRIPTION FACTOR, ARE RESPONSIBLE FOR LIMITING AUTOIMMUNITY AND CHRONIC INFLAMMATION. WE SHOWED THAT A WELL-CHARACTERIZED FOXP3(GFP) REPORTER MOUSE, WHICH EXPRESSES AN N-TERMINAL GFP-FOXP3 FUSION PROTEIN, IS A HYPOMORPH THAT CAUSES PROFOUNDLY ACCELERATED AUTOIMMUNE DIABETES ON A NOD BACKGROUND. ALTHOUGH NATURAL TREG CELL DEVELOPMENT AND IN VITRO FUNCTION ARE NOT MARKEDLY ALTERED IN FOXP3(GFP) NOD AND C57BL/6 MICE, TREG CELL FUNCTION IN INFLAMMATORY ENVIRONMENTS WAS PERTURBED AND TGF-BETA-INDUCED TREG CELL DEVELOPMENT WAS REDUCED. FOXP3(GFP) WAS UNABLE TO INTERACT WITH THE HISTONE ACETYLTRANSFERASE TIP60, THE HISTONE DEACETYLASE HDAC7, AND THE IKAROS FAMILY ZINC FINGER 4, EOS, WHICH LED TO REDUCED FOXP3 ACETYLATION AND ENHANCED K48-LINKED POLYUBIQUITYLATION. COLLECTIVELY THIS RESULTS IN AN ALTERED TRANSCRIPTIONAL LANDSCAPE AND REDUCED FOXP3-MEDIATED GENE REPRESSION, NOTABLY AT THE HALLMARK IL-2 PROMOTER. LOSS OF CONTROLLED FOXP3-DRIVEN EPIGENETIC MODIFICATION LEADS TO TREG CELL INSUFFICIENCY THAT ENABLES AUTOIMMUNITY IN SUSCEPTIBLE ENVIRONMENTS. 2012 12 2080 33 EPIGENETIC DNA METHYLATION OF EBI3 MODULATES HUMAN INTERLEUKIN-35 FORMATION VIA NFKB SIGNALING: A PROMISING THERAPEUTIC OPTION IN ULCERATIVE COLITIS. ULCERATIVE COLITIS (UC), A SEVERE CHRONIC DISEASE WITH UNCLEAR ETIOLOGY THAT IS ASSOCIATED WITH INCREASED RISK FOR COLORECTAL CANCER, IS ACCOMPANIED BY DYSREGULATION OF CYTOKINES. EPSTEIN-BARR VIRUS-INDUCED GENE 3 (EBI3) ENCODES A SUBUNIT IN THE UNIQUE HETERODIMERIC IL-12 CYTOKINE FAMILY OF EITHER PRO- OR ANTI-INFLAMMATORY FUNCTION. AFTER HAVING RECENTLY DEMONSTRATED THAT UPREGULATION OF EBI3 BY HISTONE ACETYLATION ALLEVIATES DISEASE SYMPTOMS IN A DEXTRAN SULFATE SODIUM (DSS)-TREATED MOUSE MODEL OF CHRONIC COLITIS, WE NOW AIMED TO EXAMINE A POSSIBLE FURTHER EPIGENETIC REGULATION OF EBI3 BY DNA METHYLATION UNDER INFLAMMATORY CONDITIONS. TREATMENT WITH THE DNA METHYLTRANSFERASE INHIBITOR (DNMTI) DECITABINE (DAC) AND TNFALPHA LED TO SYNERGISTIC UPREGULATION OF EBI3 IN HUMAN COLON EPITHELIAL CELLS (HCEC). USE OF DIFFERENT SIGNALING PATHWAY INHIBITORS INDICATED NFKAPPAB SIGNALING WAS NECESSARY AND PROPORTIONAL TO THE SYNERGISTIC EBI3 INDUCTION. MALDI-TOF/MS AND HPLC-ESI-MS/MS ANALYSIS OF DAC/TNFALPHA-TREATED HCEC IDENTIFIED IL-12P35 AS THE MOST PROBABLE BINDING PARTNER TO FORM A FUNCTIONAL PROTEIN. EBI3/IL-12P35 HETERODIMERS (IL-35) INDUCE THEIR OWN GENE UPREGULATION, SOMETHING THAT WAS INDEED OBSERVED IN HCEC CULTURED WITH MEDIA FROM PREVIOUSLY DAC/TNFALPHA-TREATED HCEC. THESE RESULTS SUGGEST THAT UNDER INFLAMMATORY AND DEMETHYLATING CONDITIONS THE UPREGULATION OF EBI3 RESULTS IN THE FORMATION OF ANTI-INFLAMMATORY IL-35, WHICH MIGHT BE CONSIDERED AS A THERAPEUTIC TARGET IN COLITIS. 2021 13 374 26 AN ENDOSIRNA-BASED REPRESSION MECHANISM COUNTERACTS TRANSPOSON ACTIVATION DURING GLOBAL DNA DEMETHYLATION IN EMBRYONIC STEM CELLS. ERASURE OF DNA METHYLATION AND REPRESSIVE CHROMATIN MARKS IN THE MAMMALIAN GERMLINE LEADS TO RISK OF TRANSCRIPTIONAL ACTIVATION OF TRANSPOSABLE ELEMENTS (TES). HERE, WE USED MOUSE EMBRYONIC STEM CELLS (ESCS) TO IDENTIFY AN ENDOSIRNA-BASED MECHANISM INVOLVED IN SUPPRESSION OF TE TRANSCRIPTION. IN ESCS WITH DNA DEMETHYLATION INDUCED BY ACUTE DELETION OF DNMT1, WE SAW AN INCREASE IN SENSE TRANSCRIPTION AT TES, RESULTING IN AN ABUNDANCE OF SENSE/ANTISENSE TRANSCRIPTS LEADING TO HIGH LEVELS OF ARGONAUTE2 (AGO2)-BOUND SMALL RNAS. INHIBITION OF DICER OR AGO2 EXPRESSION REVEALED THAT SMALL RNAS ARE INVOLVED IN AN IMMEDIATE RESPONSE TO DEMETHYLATION-INDUCED TRANSPOSON ACTIVATION, WHILE THE DEPOSITION OF REPRESSIVE HISTONE MARKS FOLLOWS AS A CHRONIC RESPONSE. IN VIVO, WE ALSO FOUND TE-SPECIFIC ENDOSIRNAS PRESENT DURING PRIMORDIAL GERM CELL DEVELOPMENT. OUR RESULTS SUGGEST THAT ANTISENSE TE TRANSCRIPTION IS A "TRAP" THAT ELICITS AN ENDOSIRNA RESPONSE TO RESTRAIN ACUTE TRANSPOSON ACTIVITY DURING EPIGENETIC REPROGRAMMING IN THE MAMMALIAN GERMLINE. 2017 14 3875 29 KDM2A DEFICIENCY IN MACROPHAGES ENHANCES THERMOGENESIS TO PROTECT MICE AGAINST HFD-INDUCED OBESITY BY ENHANCING H3K36ME2 AT THE PPARG LOCUS. KDM2A CATALYZES H3K36ME2 DEMETHYLATION TO PLAY AN INTRIGUING EPIGENETIC REGULATORY ROLE IN CELL PROLIFERATION, DIFFERENTIATION, AND APOPTOSIS. HEREIN WE FOUND THAT MYELOID-SPECIFIC KNOCKOUT OF KDM2A (LYSM-CRE-KDM2A(F/F), KDM2A(-/-)) PROMOTED MACROPHAGE M2 PROGRAM BY REPROGRAMING METABOLIC HOMEOSTASIS THROUGH ENHANCING FATTY ACID UPTAKE AND LIPOLYSIS. KDM2A(-/-) INCREASED H3K36ME2 LEVELS AT THE PPARG LOCUS ALONG WITH AUGMENTED CHROMATIN ACCESSIBILITY AND STAT6 RECRUITMENT, WHICH RENDERED MACROPHAGES WITH PREFERENTIAL M2 POLARIZATION. THEREFORE, THE KDM2A(-/-) MICE WERE HIGHLY PROTECTED FROM HIGH-FAT DIET (HFD)-INDUCED OBESITY, INSULIN RESISTANCE, AND HEPATIC STEATOSIS, AND FEATURED BY THE REDUCED ACCUMULATION OF ADIPOSE TISSUE MACROPHAGES AND REPRESSED CHRONIC INFLAMMATION FOLLOWING HFD CHALLENGE. PARTICULARLY, KDM2A(-/-) MACROPHAGES PROVIDED A MICROENVIRONMENT IN FAVOR OF THERMOGENESIS. UPON HFD OR COLD CHALLENGE, THE KDM2A(-/-) MICE MANIFESTED HIGHER CAPACITY FOR INDUCING ADIPOSE BROWNING AND BEIGING TO PROMOTE ENERGY EXPENDITURE. COLLECTIVELY, OUR FINDINGS DEMONSTRATE THE IMPORTANCE OF KDM2A-MEDIATED H3K36 DEMETHYLATION IN ORCHESTRATING MACROPHAGE POLARIZATION, PROVIDING NOVEL INSIGHT THAT TARGETING KDM2A IN MACROPHAGES COULD BE A VIABLE THERAPEUTIC APPROACH AGAINST OBESITY AND INSULIN RESISTANCE. 2021 15 6579 23 TREFOIL FACTORS AND HUMAN GASTRIC CANCER (REVIEW). TFF1/PS2, TFF2/SP AND TFF3/ITF ARE SOLUBLE PEPTIDES WITH TREFOIL DOMAIN(S) AND C-TERMINAL DIMERIZATION DOMAIN, WHICH ARE CONSERVED AMONG HUMAN, COW, MOUSE AND RAT. TFF1 MRNA IS EXPRESSED IN STOMACH (MUCOUS CELLS IN FUNDUS AND ANTRUM), TFF2 MRNA IN STOMACH (MUCOUS NECK CELLS IN FUNDUS AND BASAL CELLS IN ANTRAL AND PYLORIC GLANDS) AND DUODENUM (BRUNNER'S GLAND), TFF3 MRNA IN SMALL INTESTINE AND LARGE INTESTINE (GOBLET CELLS). EXPRESSION OF TFF1, TFF2 AND TFF3 MRNAS ARE DIFFERENTIALLY REGULATED BY FGF2/BFGF, FGF7/KGF, ESTROGEN, ASPIRIN, ARACHIDONIC ACID, X-RAY IRRADIATION, AND HYDROGEN PEROXIDE. GASTRIC CANCER IS CLASSIFIED INTO THE INTESTINAL TYPE AND THE DIFFUSE TYPE. TFF MRNAS ARE PREFERENTIALLY EXPRESSED IN DIFFUSE-TYPE GASTRIC CANCER CELLS. CUSTOM-MADE MICROARRAY (TFF MRNAS) AND ELISA (TFF PROTEINS) MIGHT BE APPLICABLE FOR SCREENING METHODS OF PERITONEAL AND BONE MARROW DISSEMINATION FROM DIFFUSE-TYPE GASTRIC CANCER. TFF1 AND TFF2 MRNAS ARE FREQUENTLY DOWN-REGULATED IN INTESTINAL-TYPE GASTRIC CANCER. TFF1 GENE, INACTIVATED BY DELETION, MISSENSE MUTATION AND PROMOTER HYPERMETHYLATION, IS A TUMOR SUPPRESSOR GENE IMPLICATED IN GASTRIC CANCER. TFF2 IS A CANDIDATE TUMOR SUPPRESSOR GENE; HOWEVER, GENETIC AND EPIGENETIC ALTERATIONS OF TFF2 GENE IN HUMAN GASTRIC CANCER REMAIN UNCLEAR. TFF1, TFF2 AND TFF3 PLAY KEY ROLES IN MUCOSAL PROTECTION THROUGH MUCOUS-BARRIER FORMATION, AND ALSO IN MUCOSAL REPAIR THROUGH PROMOTION OF RESTITUTION AFTER INJURY. PATIENTS WITH CHRONIC ATROPHIC GASTRITIS AND THOSE WITH ULCERATIVE COLITIS ARE AT RISK OF GASTRIC CANCER AND COLORECTAL CANCER, RESPECTIVELY. TFF1, TFF2 AND TFF3 PROTEINS MIGHT BE APPLICABLE FOR CHEMOPREVENTION OF GASTROINTESTINAL CANCER ASSOCIATED WITH CHRONIC PERSISTENT INFLAMMATION. 2003 16 5863 24 SUPPRESSION OF ALLERGIC ASTHMA BY LOSS OF FUNCTION OF MIZ1-MEDIATED TH1 SKEWING. ASTHMA IS THE MOST PREVALENT CHRONIC RESPIRATORY DISEASE WORLDWIDE. THERE IS CURRENTLY NO CURE, AND IT REMAINS AN IMPORTANT CAUSE OF MORBIDITY AND MORTALITY. HERE WE REPORT THAT LUNG-SPECIFIC LOSS OF FUNCTION OF THE TRANSCRIPTION FACTOR MIZ1 (C-MYC-INTERACTING ZINC FINGER PROTEIN-1) UPREGULATES THE PRO-T-HELPER CELL TYPE 1 CYTOKINE IL-12. UPREGULATION OF IL-12 IN TURN STIMULATES A TH1 RESPONSE, THEREBY COUNTERACTING T-HELPER CELL TYPE 2 RESPONSE AND PREVENTING THE ALLERGIC RESPONSE IN MOUSE MODELS OF HOUSE DUST MITE- AND OVA (OVALBUMIN)-INDUCED ASTHMA. USING TRANSGENIC MICE EXPRESSING CRE UNDER A CELL-SPECIFIC PROMOTER, WE DEMONSTRATE THAT MIZ1 ACTS IN LUNG EPITHELIAL CELLS AND DENDRITIC CELLS IN ASTHMA. CHROMATIN IMMUNOPRECIPITATION COUPLED WITH HIGH-THROUGHPUT DNA SEQUENCING OR QUANTITATIVE PCR REVEALS THE BINDING OF MIZ1 ON THE IL12 PROMOTER INDICATING DIRECT REPRESSION OF IL-12 BY MIZ1. IN ADDITION, HDAC1 (HISTONE DEACETYLASE 1) IS RECRUITED TO THE IL12 PROMOTER IN A MIZ1-DEPDENENT MANNER, SUGGESTING EPIGENETIC REPRESSION OF IL12 BY MIZ1. FURTHERMORE, MIZ1 IS UPREGULATED IN THE LUNGS OF ASTHMATIC MICE. OUR DATA TOGETHER SUGGEST THAT MIZ1 IS UPREGULATED DURING ASTHMA, WHICH IN TURN PROMOTES ASTHMA PATHOGENESIS BY PREVENTING TH1 SKEWING THROUGH THE TRANSCRIPTIONAL REPRESSION OF IL-12. 2022 17 673 28 BRAHMA-RELATED GENE 1 (BRG1) EPIGENETICALLY REGULATES CAM ACTIVATION DURING HYPOXIC PULMONARY HYPERTENSION. AIMS: ESTABLISHMENT OF AN INFLAMMATORY MILIEU FOLLOWING ELEVATED LEUKOCYTE ADHESION TO THE VASCULAR ENDOTHELIUM, WHICH IS MEDIATED BY TRANSCRIPTIONAL ACTIVATION OF CELL ADHESION MOLECULES (CAMS), CONTRIBUTES TO THE PATHOGENESIS OF CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION (HPH). THE EPIGENETIC SWITCH THAT DICTATES CAM TRANSACTIVATION IN RESPONSE TO HYPOXIA IN ENDOTHELIAL CELLS LEADING UP TO HPH IS NOT FULLY APPRECIATED. METHODS AND RESULTS: WE REPORT HERE THAT BRAHMA-RELATED GENE 1 (BRG1) AND BRAHMA (BRM), TWO CATALYTIC COMPONENTS OF THE MAMMALIAN CHROMATIN REMODELLING COMPLEX, WERE INDUCED IN CULTURED ENDOTHELIAL CELLS CHALLENGED WITH HYPOXIA IN VITRO AS WELL AS IN PULMONARY ARTERIES IN AN ANIMAL MODEL OF HPH. OVER-EXPRESSION OF BRG1/BRM ENHANCED, WHILE THE DEPLETION OF BRG1/BRM ATTENUATED, CAM TRANSACTIVATION AND ADHESION OF LEUKOCYTES. ENDOTHELIAL-SPECIFIC DELETION OF BRG1/BRM AMELIORATED VASCULAR INFLAMMATION AND HPH IN MICE. CHROMATIN IMMUNOPRECIPITATION (CHIP) AND RE-CHIP ASSAYS REVEALED THAT HYPOXIA UP-REGULATED THE OCCUPANCIES OF BRG1 AND BRM ON CAM PROMOTERS IN A NUCLEAR FACTOR KAPPAB (NF-KAPPAB) -DEPENDENT MANNER. FINALLY, BRG1 AND BRM ACTIVATED CAM TRANSCRIPTION BY ALTERING THE CHROMATIN STRUCTURE SURROUNDING THE CAM PROMOTERS. CONCLUSION: OUR DATA SUGGEST THAT BRG1 PROVIDES THE CRUCIAL EPIGENETIC LINK TO HYPOXIA-INDUCED CAM INDUCTION AND LEUKOCYTE ADHESION THAT ENGENDERS ENDOTHELIAL MALFUNCTION AND PATHOGENESIS OF HPH. AS SUCH, TARGETING BRG1 IN ENDOTHELIAL CELLS MAY YIELD PROMISING STRATEGIES IN THE INTERVENTION AND/OR PREVENTION OF HPH. 2013 18 35 26 A CHROMATIN ACTIVITY-BASED CHEMOPROTEOMIC APPROACH REVEALS A TRANSCRIPTIONAL REPRESSOME FOR GENE-SPECIFIC SILENCING. IMMUNE CELLS DEVELOP ENDOTOXIN TOLERANCE (ET) AFTER PROLONGED STIMULATION. ET INCREASES THE LEVEL OF A REPRESSION MARK H3K9ME2 IN THE TRANSCRIPTIONALLY SILENT CHROMATIN SPECIFICALLY ASSOCIATED WITH PRO-INFLAMMATORY GENES. HOWEVER, IT IS NOT CLEAR WHAT PROTEINS ARE FUNCTIONALLY INVOLVED IN THIS PROCESS. HERE WE SHOW THAT A NOVEL CHROMATIN ACTIVITY-BASED CHEMOPROTEOMIC (CHAC) APPROACH CAN DISSECT THE FUNCTIONAL CHROMATIN PROTEIN COMPLEXES THAT REGULATE ET-ASSOCIATED INFLAMMATION. USING UNC0638 THAT BINDS THE ENZYMATICALLY ACTIVE H3K9-SPECIFIC METHYLTRANSFERASE G9A/GLP, CHAC REVEALS THAT G9A IS CONSTITUTIVELY ACTIVE AT A G9A-DEPENDENT MEGA-DALTON REPRESSOME IN PRIMARY ENDOTOXIN-TOLERANT MACROPHAGES. G9A/GLP BROADLY IMPACTS THE ET-SPECIFIC REPROGRAMMING OF THE HISTONE CODE LANDSCAPE, CHROMATIN REMODELLING AND THE ACTIVITIES OF SELECT TRANSCRIPTION FACTORS. WE DISCOVER THAT THE G9A-DEPENDENT EPIGENETIC ENVIRONMENT PROMOTES THE TRANSCRIPTIONAL REPRESSION ACTIVITY OF C-MYC FOR GENE-SPECIFIC CO-REGULATION OF CHRONIC INFLAMMATION. CHAC MAY ALSO BE APPLICABLE TO DISSECT OTHER FUNCTIONAL PROTEIN COMPLEXES IN THE CONTEXT OF PHENOTYPIC CHROMATIN ARCHITECTURES. 2014 19 5228 24 PRMT7 TARGETS OF FOXM1 CONTROLS ALVEOLAR MYOFIBROBLAST PROLIFERATION AND DIFFERENTIATION DURING ALVEOLOGENESIS. ALTHOUGH ABERRANT ALVEOLAR MYOFIBROBLASTS (AMYFS) PROLIFERATION AND DIFFERENTIATION ARE OFTEN ASSOCIATED WITH ABNORMAL LUNG DEVELOPMENT AND DISEASES, SUCH AS BRONCHOPULMONARY DYSPLASIA (BPD), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), AND IDIOPATHIC PULMONARY FIBROSIS (IPF), EPIGENETIC MECHANISMS REGULATING PROLIFERATION AND DIFFERENTIATION OF AMYFS REMAIN POORLY UNDERSTOOD. PROTEIN ARGININE METHYLTRANSFERASE 7 (PRMT7) IS THE ONLY REPORTED TYPE III ENZYME RESPONSIBLE FOR MONOMETHYLATION OF ARGININE RESIDUE ON BOTH HISTONE AND NONHISTONE SUBSTRATES. HERE WE PROVIDE EVIDENCE FOR PRMT7'S FUNCTION IN REGULATING AMYFS PROLIFERATION AND DIFFERENTIATION DURING LUNG ALVEOLOGENESIS. IN PRMT7-DEFICIENT MICE, WE FOUND REDUCED AMYFS PROLIFERATION AND DIFFERENTIATION, ABNORMAL ELASTIN DEPOSITION, AND FAILURE OF ALVEOLAR SEPTUM FORMATION. WE FURTHER SHOWN THAT ONCOGENE FORKHEAD BOX M1 (FOXM1) IS A DIRECT TARGET OF PRMT7 AND THAT PRMT7-CATALYZED MONOMETHYLATION AT HISTONE H4 ARGININE 3 (H4R3ME1) DIRECTLY ASSOCIATE WITH CHROMATIN OF FOXM1 TO ACTIVATE ITS TRANSCRIPTION, AND THEREBY REGULATE OF CELL CYCLE-RELATED GENES TO INHIBIT AMYFS PROLIFERATION AND DIFFERENTIATION. OVEREXPRESSION OF FOXM1 IN ISOLATED MYOFIBROBLASTS (MYFS) SIGNIFICANTLY RESCUED PRMT7-DEFICIENCY-INDUCED CELL PROLIFERATION AND DIFFERENTIATION DEFECTS. THUS, OUR RESULTS REVEAL A NOVEL EPIGENETIC MECHANISM THROUGH WHICH PRMT7-MEDIATED HISTONE ARGININE MONOMETHYLATION ACTIVATES FOXM1 TRANSCRIPTIONAL EXPRESSION TO REGULATE AMYFS PROLIFERATION AND DIFFERENTIATION DURING LUNG ALVEOLOGENESIS AND MAY REPRESENT A POTENTIAL TARGET FOR INTERVENTION IN PULMONARY DISEASES. 2021 20 866 30 CHRONIC ACTIVATION OF MUC1-C IN WOUND REPAIR PROMOTES PROGRESSION TO CANCER STEM CELLS. THE MUCIN 1 (MUC1) GENE EMERGED IN MAMMALS TO AFFORD PROTECTION OF BARRIER EPITHELIAL TISSUES FROM THE EXTERNAL ENVIRONMENT. MUC1 ENCODES A TRANSMEMBRANE C-TERMINAL (MUC1-C) SUBUNIT THAT IS ACTIVATED BY LOSS OF HOMEOSTASIS AND INDUCES INFLAMMATORY, PROLIFERATIVE, AND REMODELING PATHWAYS ASSOCIATED WITH WOUND REPAIR. AS A CONSEQUENCE, CHRONIC ACTIVATION OF MUC1-C PROMOTES LINEAGE PLASTICITY, EPIGENETIC REPROGRAMMING, AND CARCINOGENESIS. IN DRIVING CANCER PROGRESSION, MUC1-C IS IMPORTED INTO THE NUCLEUS, WHERE IT INDUCES NF-KAPPAB INFLAMMATORY SIGNALING AND THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). MUC1-C REPRESSES GENE EXPRESSION BY ACTIVATING (I) DNA METHYLTRANSFERASE 1 (DNMT1) AND DNMT3B, (II) POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) AND PRC2, AND (III) THE NUCLEOSOME REMODELING AND DEACETYLASE (NURD) COMPLEX. PRC1/2-MEDIATED GENE REPRESSION IS COUNTERACTED BY THE SWI/SNF CHROMATIN REMODELING COMPLEXES. MUC1-C ACTIVATES THE SWI/SNF BAF AND PBAF COMPLEXES IN CANCER STEM CELL (CSC) MODELS WITH THE INDUCTION OF GENOME-WIDE DIFFERENTIALLY ACCESSIBLE REGIONS AND EXPRESSED GENES. MUC1-C REGULATES CHROMATIN ACCESSIBILITY OF ENHANCER-LIKE SIGNATURES IN ASSOCIATION WITH THE INDUCTION OF THE YAMANAKA PLURIPOTENCY FACTORS AND RECRUITMENT OF JUN AND BAF, WHICH PROMOTE INCREASES IN HISTONE ACTIVATION MARKS AND OPENING OF CHROMATIN. THESE AND OTHER FINDINGS DESCRIBED IN THIS REVIEW HAVE UNCOVERED A PIVOTAL ROLE FOR MUC1-C IN INTEGRATING LINEAGE PLASTICITY AND EPIGENETIC REPROGRAMMING, WHICH ARE TRANSIENT IN WOUND REPAIR AND SUSTAINED IN PROMOTING CSC PROGRESSION. 2022